Where is Valentis located?

Valentis is headquartered in Vilnius, Lithuania.

How many employees does Valentis have?

As of Sep 30, 2026, the latest employee count at Valentis is 69.

Is Valentis a funded company?

Valentis is a funded company, having raised an undisclosed amount across 2 funding rounds to date. The company's 1st funding round was a $***** Post IPO round.

When was the latest funding round of Valentis?

Valentis' latest funding was a $***** Post IPO round on Jan 07, 2002, with participation from 0 investor.

Where does Valentis rank among its competitors?

Valentis ranks 43rd amongst 444 active competitors, of which 26 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was SAI Parenterals, which secured $5.83M in Jul, 2025.

Who are the top competitors of Valentis?

Valentis' top competitors include Patheon, Panacea Biotec and EirGenix. Among them, SAI Parenterals secured the most recent funding round in July, 2025.

Valentis - 2026 Company Profile, Funding & Competitors

Valentis is a public company based in Vilnius (Lithuania), founded in 1919. It operates as a Manufacturer of a range of pharmaceutical products. Valentis has raised an undisclosed amount in funding. The company has 444 active competitors, including 26 funded and 99 that have exited. Its top competitors include companies like Patheon, Panacea Biotec and EirGenix.

Company Details

Website: www.valentis.com/
Email ID: *****@valentis.lt

Key Metrics

Founded Year

1919

Location

Vilnius, Lithuania

Stage

Public

Latest Funding Round

Post IPO, Jan 07, 2002, $*****

Investors

BCM Technologies & 1 more

Ranked

43^rd among 444 active competitors

Employee Count

69 as on Sep 30, 2026

Similar Companies

Patheon & 312 more

Exit Details

Public

View Valentis' full profile

Valentis got listed on Sep 16, 1997.

Click here to take a look at Valentis's IPO in detail

Valentis has raised funding over 2 rounds. Valentis has 2 institutional investors.

Here is the list of recent funding rounds of Valentis:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 07, 2002	6817263	Post IPO	9820138	8419737	4883453	2734535

Access funding benchmarks and valuations. Sign up today!

View details of Valentis's funding rounds and investors

Valentis' employee count trend

Valentis has 69 employees as of Sep 26. Here is Valentis's employee count trend over the years:

Uncover Valentis' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Valentis include Patheon, Panacea Biotec and EirGenix. Here is the list of Top 10 competitors of Valentis, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Patheon 1974, Durham (United States), Acquired	Global CDMO providing integrated drug development, clinical trials, and manufacturing services	$141M	Frazier Healthcare Partners, Audax Group & 3 others	75/100
2nd	Panacea Biotec 1984, Ambala (India), Public	Developer of biosimilars, vaccines and natural products	-	India Resurgence Fund, Department of Biotechnology ... & 1 others	62/100
3rd	EirGenix 2012, Taipei (Taiwan), Public	Contract development and manufacturing organization for biologics	-	CDIB Capital Group, Taiwania Capital & 3 others	58/100
4th	Kemwell Biopharma 1980, Bengaluru (India), Acquired	A biologics CDMO providing integrated development and manufacturing	$8.81M	Subhashfamilytrust & 4 others	57/100
5th	Daewoong Pharmaceutical 1945, Seoul (South Korea), Public	Developer of therapies for treating gastrointestinal disorders	-	Business Innovation Network	57/100
6th	KBI Biopharma 1996, Durham (United States), Acquired	Provider of protein formulation, process & cell line development, and cGMP services	$21M	Ballast Point Ventures, NCBiotech & 1 others	56/100
7th	SAI Parenterals 2001, Hyderabad (India), Public	Provider of parenteral products and pharmaceutical services	$5.83M	Samarsh Capital, Blue Lotus Capital & 3 others	56/100
8th	Insud Pharma 1977, Madrid (Spain), Funding Raised	Developer and manufacturer of finished formulations, APIs and monoclonal antibodies	-	Gates	56/100
9th	Omnia Biologics 2001, Rockville (United States), Acquired	Process development and manufacturing services for biologics	$25.4M	Medipost, JLABS	56/100
10th	Upperton 1999, Nottingham (United Kingdom), Acquired	Spray drying and drug formulation services	-	Inflexion, Europa	56/100
43rd	Valentis 1919, Vilnius (Lithuania), Public	Manufacturer of a range of pharmaceutical products	-	BCM Technologies, Reference Capital Management	44/100